Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 2/20 | 0.56 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LTA | P01374 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5411760 | 0.89 | P2RY6 (0.47) | MIFP2RY6CA1CA2HSD17B10 | |
| Bitoscanate SCHEMBL157128 | 0.86 | MIF (0.72) | MIFP2RY6CA1CA2HSD17B10 | |
| SCHEMBL20184801 | 0.78 | SLC22A2 (0.44) | MIFP2RY6CA1CA2SLC22A2 | |
| SCHEMBL1548531 | 0.78 | MIF (0.62) | MIFP2RY6CA1CA2HSD17B10 | |
| SCHEMBL8506851 | 0.77 | P2RY6 (0.40) | MIFP2RY6CA1CA2HSD17B10 | |
| SCHEMBL14344845 | 0.76 | MIF (0.59) | MIFP2RY6CA1CA2HSD17B10 | |
| SCHEMBL25305038 | 0.74 | SLC22A2 (0.41) | MIFP2RY6CA1CA2SLC22A2 | |
| SCHEMBL331404 | 0.74 | MIF (0.56) | MIFP2RY6CA1CA2HSD17B10 | |
| SCHEMBL449738 | 0.74 | MIF (0.56) | MIFP2RY6CA1CA2HSD17B10 | |
| SCHEMBL13881813 | 0.74 | MIF (0.56) | MIFP2RY6CA1CA2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 859 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12402638-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2025-09-02 | — | — | US | claimed |
| CN-115515998-B | Synthesis of polyurethanes by chain growth copolymerization | 伊夫·雅努 | 2025-06-24 | — | — | CN | claimed |
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | claimed |
| CN-116947780-B | Preparation method of thiazolidine-4-thioketone derivative | 华侨大学 | 2025-06-03 | — | — | CN | claimed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | claimed |
| US-12232516-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2025-02-25 | — | — | US | claimed |
| US-12193465-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2025-01-14 | — | — | US | claimed |
| CN-119080660-A | Thiosemicarbazide menthyl formate compound, preparation method and application thereof | 南京林业大学 | 2024-12-06 | — | — | CN | claimed |
| CN-118738556-A | Electrolyte and lithium metal battery | 蜂巢能源科技股份有限公司 | 2024-10-01 | — | — | CN | claimed |
| CN-117924210-A | Preparation method of 2-iminothiazolidine-4-ketone compound | 赣南师范大学 | 2024-04-26 | — | — | CN | claimed |
| CN-105267967-A | Combined application of isothiocyanate-type compound and anti-cancer drug acting or affecting DNA | WUXI JC PHARMACAUTICAL TECHNOLOGY INC | 2016-01-27 | — | — | CN | claimed |
| CN-104415332-A | Combined application between isothiocyanate-type compound and kinase inhibitor medicine in treatment of cancer | WUXI JC PHARMACAUTICAL TECHNOLOGY INC | 2015-03-18 | — | — | CN | claimed |
| US-8940434-B2 | Electrolyte additive and electrolyte and lithium rechargeable battery including same | SAMSUNG SDI CO., LTD. (KR) | 2015-01-27 | — | — | US | claimed |
| CN-104117064-A | Combined application of isothiocyanate compound and hormone medicine | WUXI JC PHARMACAUTICAL TECHNOLOGY INC | 2014-10-29 | — | — | CN | claimed |
| CN-103992265-A | Double tribromo 1,3-bipyridine onium salt dimethylmethane, and preparation method, application method, recovery method and application thereof | UNIV XI AN JIAOTONG | 2014-08-20 | — | — | CN | claimed |
| CN-103864655-A | Synthetic method of dehydroabietic acid group thiourea derivative | UNIV GUANGXI | 2014-06-18 | — | — | CN | claimed |
| US-20140134480-A1 | ELECTROLYTE ADDITIVE AND ELECTROLYTE AND LITHIUM RECHARGEABLE BATTERY INCLUDING SAME | SAMSUNG SDI CO., LTD. (KR) | 2014-05-15 | — | — | US | claimed |
| WO-2010065329-A2 | NANOPARTICLES FOR CANCER TREATMENT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-06-10 | — | — | WO | claimed |
| US-20060241178-A1 | Compositions and methods for treating lung cancer | IMMUNEGUARD LLC (US) | 2006-10-26 | — | — | US | claimed |
| WO-2004060365-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG CANCER | AMERICAN HEALTH FOUNDATION (US) | 2004-07-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140134480-A1 | ELECTROLYTE ADDITIVE AND ELECTROLYTE AND LITHIUM RECHARGEABLE BATTERY INCLUDING SAME | TST, SLC26A3, CLCN2 | MIF 3547/4885P2RY6 3427/4885CA1 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.